CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 36 filers reported holding CATABASIS PHARMACEUTICALS IN in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $2,465,000 | -41.4% | 682,940 | -0.1% | 0.10% | -48.5% |
| Q3 2016 | $4,210,000 | +76.8% | 683,375 | +6.2% | 0.20% | +108.5% |
| Q2 2016 | $2,381,000 | -26.6% | 643,580 | 0.0% | 0.09% | -31.9% |
| Q1 2016 | $3,244,000 | -36.4% | 643,580 | 0.0% | 0.14% | -33.3% |
| Q4 2015 | $5,104,000 | +0.4% | 643,580 | +2.4% | 0.21% | +5.1% |
| Q3 2015 | $5,084,000 | -43.6% | 628,482 | -14.8% | 0.20% | -34.3% |
| Q2 2015 | $9,012,000 | – | 738,055 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $4,572,000 | 5.05% |
| Clarus Ventures, LLC | 2,752,488 | $4,404,000 | 3.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 388,030 | $621,000 | 0.12% |
| Rhenman & Partners Asset Management AB | 310,756 | $497,000 | 0.08% |
| BOSTON FAMILY OFFICE LLC | 24,467 | $39,000 | 0.01% |
| OPPENHEIMER & CO INC | 90,000 | $144,000 | 0.00% |
| Alyeska Investment Group, L.P. | 221,281 | $354,000 | 0.00% |
| A.R.T. Advisors, LLC | 46,747 | $74,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 101,347 | $162,000 | 0.00% |
| Acrospire Investment Management LLC | 680 | $1,000 | 0.00% |